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ABSTRACT
Clavulanate is a highly effective inhibitor of extended-spectrum b-lactamases (ESBLs) in detection tests,
but the commercial amoxycillin–clavulanate and ticarcillin–clavulanate combinations have borderline
activity, at best, against most ESBL producers. Oxyimino-cephalosporin–clavulanate combinations are
active in vitro against most ESBL-producing Escherichia coli and Klebsiella spp. isolates at £1–2 mg ⁄L but
are compromised against Enterobacter spp., whether ESBL-producing or not, where clavulanate-induced
AmpC enzymes attack the cephalosporin. These problems can be overcome by combining clavulanate
with cefepime or cefpirome, which are more stable to AmpC. The resulting combinations are active
in vitro at £1 mg ⁄L against virtually all ESBL-producing Enterobacteriaceae, including Enterobacter spp.
AmpC-inducible organisms, such as Enterobacter, are less of a concern in the community, where ESBL-
producing E. coli strains present growing problems, and where new oral treatments would be useful.
Cefpodoxime–clavulanate is not ideal, in terms of pharmacological matching, but might be ﬁt for
purpose, certainly in comparison with fosfomycin and nitrofurantoin, which are used at present but
which are suitable only for lower urinary tract infections. Clinical development of clavulanate with
cefepime, cefpirome or cefpodoxime does not seem likely in the West, considering ownership and patent
issues. Cefpisome-tazobactum is, however, being launched in India, where the licensing regime is more
liberal. Combinations of clavulanate with modern anti-methicillin-resistant Staphylococcus aureus
cephalosporins also deserve investigation, as these compounds remain labile to ESBLs.
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Clavulanate is widely used in synergy tests for
the laboratory detection of extended-spectrum
b-lactamases (ESBLs), but clavulanate combina-
tions are viewed with scepticism as treatments for
infections due to ESBL producers. The root of this
paradox is that, while clavulanate is an excellent
inhibitor of the predominant CTX-M, TEM, SHV
and VEB (not OXA and AmpC) ESBLs, it is
combined, commercially, with amoxycillin and
ticarcillin. Both of these penicillins are very
efﬁciently hydrolysed by ESBLs (and by many
other b-lactamases) and so are difﬁcult to protect
[1]. Resistance arises: (i) if an ESBL—or a classic
penicillinase—is produced copiously; (ii) if multi-
ple b-lactamases are produced; or (iii) if the
isolate also has reduced permeability or up-
regulated efﬂux [1]. A further complexity arises
from the fact that laboratory testing of b-lactam-
ase inhibitor combinations is remarkably unstan-
dardised. There are arguments for testing with a
ﬁxed penicillin ⁄ inhibitor concentration ratio, or
with a ﬁxed inhibitor concentration, but there is
no logic in preferring, as both the CLSI and British
Society for Antimicrobial Chemotherapy (BSAC)
do, a ﬁxed ratio for some combinations (e.g.,
amoxycillin–clavulanate) and a ﬁxed concentra-
tion for others (e.g., ticarcillin–clavulanate)[2,3].
In practice, many ESBL studies from the 1990s
onwards have found 50% or more of ESBL
producers to be resistant to amoxycillin–clavula-
nate and ticarcillin–clavulanate [4]. This propor-
tion is increasing as CTX-M-15 becomes the
dominant ESBL in much of Europe and Asia,
since it is often encoded by plasmids that also
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determine OXA-1, a clavulanate-resistant penicil-
linase [5–7]. The consequences are illustrated in
Fig. 1, showing the MIC distribution of amoxy-
cillin–clavulanate against 606 ESBL-producing
Escherichia coli and Klebsiella spp. isolates collected
in a 16-hospital survey in London and south-east
England in 2004, 78% of them with group 1 CTX-
M enzymes, principally CTX-M-15, often
accompanied by OXA-1 [8]. The modal MIC for
a 2:1 amoxycillin–clavulanate combination was
16 + 8 mg ⁄L, corresponding to ‘intermediate’
under BSAC, CLSI and (provisional) EUCAST
recommendations. The BSAC does have a higher
susceptible breakpoint (S £32 + 16 mg ⁄L) for uri-
nary tract infections, [2], but ‘susceptibility’ here
often reﬂects the antibiotic activity of clavulanate
alone, which has MICs of 8–16 mg ⁄L for most
E. coli isolates [1].
Despite these caveats, a minority of ESBL
producers appear to be susceptible to commercial
clavulanate combinations at or below the systemic
breakpoint, and clinical use here remains an issue
for debate. Some workers believe that the magni-
tude of inoculum effects militates against use;
others, ourselves included, contend that it is
contradictory to accept the activity of clavulanate
combinations against strains with classic penicil-
linases but to dismiss them for use against strains
with ESBLs, which are at least as susceptible to the
inhibitory activity of clavulanate [9]. Clinical
experience would resolve this debate, but there
are only a few case reports on the use of conven-
tional clavulanate combinations in infections due
to ESBL producers [10,11], along with one more
substantial recent analysis of outcomes where
these combinations were used as empirical ther-
apy in bacteraemias that transpired to be due to
E. coli with ESBLs [12]. This latter study, from
Seville, reported success with intravenous
amoxycillin–clavulanate in 10 ⁄ 11 cases, but it
should be noted that most of the isolates had
group 9 CTX-M enzymes and only required
amoxycillin–clavulanate MICs of 4–8 mg ⁄L. These
data are positive,but we would advocate great
caution, particularly in life-threatening infections,
as many producers – particularly those with the
commoner CTX-M-15 ⁄OXA-1 combination – are
less susceptible.
In principle, it should be possible to design
more effective combinations by using clavulanate
to protect an oxyimino-cephalosporin. These com-
pounds are weaker substrates than amoxycillin
and ticarcillin for ESBLs, and so are easier to
protect; moreover, they have higher afﬁnity for
the penicillin-binding proteins [13], meaning that
only a low periplasmic drug concentration is
needed to achieve antibacterial activity [7]. They
are stable to inhibitor-resistant penicillinases,
including OXA-1, meaning that strains co-pro-
ducing this enzyme should remain susceptible. In
practice, combinations of cefotaxime or ceftazi-
dime with clavulanate, 4 mg ⁄L, were active
against over 95% of ESBL-producing E. coli and
Klebsiella spp. isolates, based on the
EUCAST ⁄BSAC oxyimino-cephalosporin break-
points of 1 mg ⁄L (Table 1). Exceptions were the
minority of Klebsiella spp. isolates that also have
permeability ⁄ efﬂux lesions; these are typically
also resistant to ertapenem and, less so, to other
carbapenems [14]. The pharmacokinetics of cla-
vulanate are compatible, prima facie, with those of
cefotaxime or ceftazidime, with serum half-lives
of c. 75–90 min and the potential for three-times-
daily administration. Problems do, however, arise
with Enterobacter spp. and other genera with
AmpC b-lactamases. Speciﬁcally, inhibition of
ESBLs fails to confer susceptibility in those strains
that are also derepressed for AmpC, as these
latter enzymes continue to protect against the
oxyimino-cephalosporins. Moreover, clavulanate
can promote the synthesis of inducible AmpC
enzymes, compromising any gain achieved by
inhibition of an ESBL. The net result is that
cefotaxime–clavulanate and ceftazidime–clavula-
nate were active, at 1–2 mg ⁄L, against only half of
the ESBL-producing Enterobacter spp. isolates and
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Fig. 1. Activity of amoxycillin–clavulanate 2:1 ﬁxed ratio
vs. extended-spectrum b-lactamase (ESBL)-producing Esc-
herichia coli (black) and Klebsiella spp. (grey) collected in a
survey in south-east England in 2004 [8]. Fuller details
of the survey methods are given in the footnote to Table 1.
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that concentrations exceeding 8 mg ⁄L were
required to inhibit even 75% (Table 1). Worse,
third-generation cephalosporin–clavulanate com-
binations were antagonistic against some ESBL-
negative Enterobacter and Citrobacter freundii
isolates (Table 2), with the clavulanate-induced
AmpC attacking the partner cephalosporin. While
this antagonism (which occurs to an extent
between ticarcillin and clavulanate against
AmpC-inducible species) [15] has never been
proven to be clinically signiﬁcant, it would be a
concern in empirical usage, and might militate
against licensing.
The obvious way to circumvent these problems
is to combine clavulanatewith a cephalosporin that
is relatively more stable to AmpC, for example
cefepime or cefpirome [16]. We found cefepime–
clavulanate (Table 1) to be active at 1 mg ⁄L against
all of 380 ESBL-producing E. coli isolates tested, all
of 36ESBL-producingEnterobacter spp. isolates and
224 ⁄ 226 ESBL-producing Klebsiella spp isolates.
Cefpirome–clavulanate was active at 1 mg ⁄L
Table 1. Activity of clavulanate–cephalosporin combinations vs. extended-spectrum b-lactamase (ESBL)-producing
Enterobacteriaceae, collected in the UK in 2004
No. of isolates with indicated MIC (mg ⁄L)
£0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
Escherichia coli Cefotaxime 2 1 10 17 30 33 48 22 26 49 142
Cefotaxime + clavulanate 150 162 52 12 4
Enterobacter spp. Cefotaxime 2 5 13 5 5 5 1
Cefotaxime + clavulanate 2 4 3 5 4 3 2 6 7b
Klebsiella spp. Cefotaxime 1a 3 1 1 1 5 9 2 8 24 80 91
Cefotaxime + clavulanate 79 80 42 18 1 1 1 1 3b
E. coli Ceftazidime 9 8 30 50 14 32 42 99 70 17 3 6
Ceftazidime + clavulanate 9 100 176 82 13
Enterobacter spp. Ceftazidime 2 1 2 6 12 6 7
Ceftazidime + clavulanate 6 5 6 5 2 9 1 2b
Klebsiella spp. Ceftazidime 1 1 2 6 13 31 75 43 38 16
Ceftazidime + clavulanate 3 7 37 108 62 3 1 2 3b
E. coli Cefepime 3a 8 27 68 41 19 33 44 43 94b
Cefepime + clavulanate 308 59 10 2 1
Enterobacter spp. Cefepime 6 10 4 10 3 3
Cefepime + clavulanate 8 12 8 6 2
Klebsiella spp. Cefepime 1 9 11 6 15 34 81 69b
Cefepime + clavulanate 151 55 14 4 1 1
E. coli Cefpirome 1a 2 18 30 41 38 33 10 16 191b
Cefpirome + clavulanate 259 88 28 4 1
Enterobacter spp. Cefpirome 5 9 6 7 4 5b
Cefpirome + clavulanate 4 11 3 13 3 2
Klebsiella spp. Cefpirome 1 3 9 8 2 8 13 186b
Cefpirome + clavulanate 101 74 38 9 1 1 1 1
E. coli Cefpodoxime 2 5 7 16 38 312b
Cefpodoxime + clavulanate 2 19 214 105 29 10 1
Enterobacter spp. Cefpodoxime 3 33b
Cefpodoxime + clavulanate 3 2 3 4 4 1 19b
Klebsiella spp. Cefpodoxime 1 2 1 1 2 5 214b
Cefpodoxime + clavulanate 3 18 65 84 35 13 3 5b
aNumber of isolates with MIC at or below the stated drug concentration.
bNumber of isolates with MIC at or above the stated drug concentration.
Isolates were from the study described by Potz et al. [8]. This collected consecutive oxyimino-cephalosporin-resistant
Enterobacteriaceae from 16 hospital laboratories in London and south-east England from August to October 2004. Only
isolates conﬁrmed as having ESBLs are included in the table. MICs were determined by the BSAC agar dilution method,
with clavulanate at 4 mg ⁄L. Among the 380 E. coli isolates, the proportion with group 1 CTX-M enzymes was 74%, that with
group 9 CTX-M ESBLs was 3%, and that with SHV, TEM or other types was 15%; the corresponding proportions for the
Enterobacter isolates (n = 36) were 22%, 0%, and 78%; those for Klebsiella spp. isolates (n = 226) were 87%, 1% and 12%.
Figures in bold font are mode MICs.
Figures underlined are MIC90 values. If the mode and MIC90 coincide the number appears as both bold and underlined.
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against all the E. coli and Enterobacter spp. isolates,
with 4 ⁄ 226 ESBL-producing Klebsiella spp. isolates
being resistant. No signiﬁcant (>1 dilution)
antagonism was seen with cefepime–clavulanate
when tested against ESBL-negative AmpC
(Table 2). Cefpirome and cefepime both have
pharmacokinetics that should be compatible with
clavulanate, with a facility for three-times-daily
administration and with no obvious side-effect
risk. The resulting combinations have the potential
to be attractive alternatives to carbapenems for
severe infections due to ESBL producers.
There remains the issue of community infec-
tions—mostly of the urinary tract—due to ESBL
producers, where an oral antibiotic would be
preferred.Many ESBL producers from community
patients are resistant, not only to the cephalospo-
rins and penicillins, but also to ﬂuoroquinolones
and to trimethoprim, underscoring this need for
new oral therapies [5,8,17]. Nitrofurantoin and
fosfomycin are used therapeutically but are suit-
able only for lower urinary tract infections. More-
over, nitrofurantoin has a poor side-effect proﬁle,
particularly in the elderly. No oral partner cepha-
losporin looks as good as cefepime or cefpirome for
combination with clavulanate; however, AmpC-
inducible organisms such Enterobacter spp. are less
of a concern in the community than in the hospital,
so it might be acceptable to use an AmpC-labile
partner agent, such as cefpodoxime or ceﬁxime.
Cefpodoxime–clavulanate was active, at 1 mg ⁄L,
against 340 ⁄ 380 ESBL-producing E. coli isolates
and 205 ⁄ 226Klebsiella spp. isolates (Table 1). These
rates are at least as good as those for nitrofurantoin
and fosfomycin[8]. Moreover: (i) a 1 mg ⁄L break-
point may be too conservative for urinary tract
infections; and (ii) unlike nitrofurantoin and fosfo-
mycin, cefpodoxime–clavulanate would poten-
tially be useful in ascending urinary infections.
As an antibiotic that is ordinarily given twice-
daily rather than three-times-daily, cefpodoxime
(or ceﬁxime) is imperfectly matched to clavula-
nate, although this mismatch might be overcome
with slow-release formulations or by dividing the
dosage. An alternative would be to combine
clavulanate with mecillinam (amdinocillin), a
compound with moderate stability to both ESBLs
and AmpC enzymes, but for which the MICs for
ESBL producers rise markedly at high inoculum
[18]. Addition of clavulanate prevented this rise,
with mecillinam MICs for 28 ⁄ 29 ESBL-positive
E. coli and Klebsiella spp. isolates remaining
£4 mg ⁄L in high-inoculum tests in the presence
of 4 mg ⁄L clavulanate, and £0.06 mg ⁄L in 21 ⁄ 29
cases. In the absence of clavulanate, 23 ⁄ 29 high-
inoculum mecillinam MICs exceeded 4 mg ⁄L for
ESBL producers [18].
Anecdotally, we are aware of two sites in the
UK where amoxycillin–clavulanate plus either
cefpodoxime or ceﬁxime has been widely and
successfully used in urinary tract infections due to
ESBL-producing E. coli, but neither has yet pub-
lished their experience, and anyone following
their example would be advised to do so with
caution and, perhaps, also to consult with their
Ethics Committee.
In summary, the commercialised clavulanate
combinations have inconsistent activity, at best,
against ESBL producers, and should be used with
great caution. Despite the successes reported by
Rodriguez-Ban˜o et al. [12], we would consider
that they are better avoided in life-threatening
infections. Combinations of clavulanate with
cefepime and cefpirome deserve evaluation as
alternatives to carbapenems in severe infections
due to ESBL producers. Cefpodoxime–clavula-
nate (or ceﬁxime–clavulanate), while imperfectly
matched, might well be better than the oral agents
presently used against urinary tract infections due
to ESBL producers in the community.
The problem lies in having these combinations
evaluated clinically. Cefepime, cefpirome, clavul-
anate and cefpodoxime were developed and
marketed by different companies (Bristol Myers
Squibb, Glaxo SmithKline and Aventis, or their
predecessors), and are now either out of patent, or
at the very end of their patent life. Who will
Table 2. Interactions of clavulanate with cefotaxime and
cefepime vs. 62 cefotaxime-susceptible AmpC-inducible
Enterobacter spp. and C. freundii
Maximum interaction Cefotaxime Cefepime
Eight-fold synergy 1 –
Four-fold synergy 3 2
Two-fold synergy 13 2
None 20 58
Two-fold antagonism 14 –
Four-fold antagonism 2 –
Eight-fold antagonism 7 –
16-fold antagonism 1 –
32-fold antagonism 1 –
Isolates were randomly selected recent isolates without
extended-spectrum b-lactamases and were susceptible to
cefotaxime and cefepime at <1 mg ⁄L in the absence of
clavulanate.
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ﬁnance the requisite phase III trials for combina-
tions of these agents, costing several hundred
million dollars?
We see two rays of hope. First, new cephalospo-
rins are being developed for their anti-methicillin-
resistant Staphylococcus aureus activity, notably
ceftobiprole and ceftaroline. These are vulnerable
to ESBLs [19,20], and manufacturers may seek to
formulate them with clavulanate or other b-lac-
tamase inhibitors so as to widen their spectra. Such
combinations would enjoy patent protection for as
long as the cephalosporins themselves. Second, it is
possible to launch a drug combination in India—a
fast-developing country with one-sixth of the
world’s population—on the basis of what, in the
West, would count as phase II data. Ceftriaxone–
sulbactam is marketed on this basis by at least one
local company (Ceftrimax, VHB Group, Mumbai,
http://www.vhbgroup.com).Whilst, in the period
between theVenicemeeting andpublication of this
supplement, Ranbaxy (http://www.ranbaxy.com)
have launched a cefepime-tazobactum combina-
tion. It will be intriguing to see the clinical results
against ESBL producers and, if these are positive,
the reactions of both western microbiologists and
companies!
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